ONCE-WEEKLY

wegovy®

semaglutide injection 2.4 mg

Actor portrayals throughout.

Wegovy® is approved for adults with MASH with liver scarring,* along with a reduced calorie diet and increased physical activity.

What could Wegovy® mean for treating MASH?

*Moderate to advanced liver scarring (fibrosis) without cirrhosis.

What is Wegovy®?

Wegovy® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring. There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy® is safe and effective for the treatment of MASH in people under 18 years of age.

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

What is **MASH?**

MASH is a serious form of fatty liver disease. Fatty liver means there's an excess buildup of fat in your liver, which, over time, can cause MASH. MASH is a serious condition in which the liver becomes inflamed and damaged (liver cells are enlarged and misshapen).

Let's break down what it means:

Metabolic = related to metabolism, how the body processes food into energy

Dysfunction = something isn't working properly

Associated = linked or connected to

Steato = fat

Hepatitis = inflammation of the liver

If MASH progresses, **liver scarring** (fibrosis) may develop. This makes it harder for your liver to do its job. If the scarring gets worse, it can turn into **cirrhosis**, the most severe stage of liver scarring that can seriously affect your health.

Fatty liver | **MASH without scarring** | **MASH with scarring** | **Cirrhosis**

If left untreated, MASH can lead to liver failure or liver cancer and is also associated with cardiovascular disease. Cardiovascular disease is the leading cause of death in people living with MASH. But when addressed as soon as possible, **MASH can often be managed and even improved through lifestyle changes and treatment.**

MASH and **metabolic dysfunction**

MASH is caused by metabolic dysfunction. That means your metabolism, or how the body processes food into energy, isn't working properly. Normally, your liver helps process nutrients, including fats and sugars, from the food you eat. When metabolism is altered, your liver begins storing too much fat. This can lead to MASH, which can further progress leading to liver scarring.

Certain health conditions are associated with an increased risk for MASH, and these may be signs of metabolic dysfunction. **If you are living with any of the health conditions below, talk to your health care professional (HCP) about your personal risk for developing MASH with liver scarring.**

- Fatty liver or family history of cirrhosis
- Type 2 diabetes or prediabetes
- Obesity
- High blood pressure
- High triglycerides (a type of fat)
- Low HDL (good cholesterol)
- Persistently elevated liver enzymes (over 6 months)
- PCOS (polycystic ovary syndrome)

Make the most of your **MASH management plan**

Commit to change, one step at a time

Managing MASH is a marathon, not a sprint. Whether you're making changes to your daily habits or starting a new medication, remember that every step counts! Stay in touch with your HCP to monitor your progress.

Eat a variety of healthy foods

A healthy diet isn't just about what foods you avoid. Within a reduced calorie diet, aim to include more fruits, vegetables, and whole grains, and ask your HCP what other foods support your liver health. Recipes from the Mediterranean diet are a great starting point.

Get moving

Try to stay active consistently. Even just 2.5 hours of moderate-intensity physical activity a week can make a difference. Always consult your HCP before trying any new workouts.

MASH, metabolic dysfunction–associated steatohepatitis.

HDL, high-density lipoprotein.

Why **Wegovy®** (semaglutide) injection 2.4 mg?

How Wegovy® was studied

Results are from Week 72 of a medical study of adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis (the most advanced form of liver scarring). 800 adults were included in the analysis. Health care professionals (HCPs) involved in the study were encouraged to optimize treatment for coexisting conditions and provide lifestyle counseling for all participants.

Reduced MASH and no worsening of liver scarring

In the study, significantly more adults taking Wegovy® achieved **a reduction in MASH and no worsening of liver scarring*** compared with those taking placebo (inactive injection). This means that more patients taking Wegovy® achieved:

- Mild to no inflammation in the liver
- No enlarged liver cells, also called ballooning
- No worsening of liver scarring

REDUCED **MASH**

63% of adults taking Wegovy® achieved reduced MASH and no worsening of liver scarring

vs **34%** of adults taking placebo

*Defined as resolution of steatohepatitis (score of 0-1 for lobular inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver scarring.

MASH, metabolic dysfunction–associated steatohepatitis.

Important Safety Information

What is the most important information I should know about Wegovy®?

Wegovy® may cause serious side effects, including:

- **Possible thyroid tumors, including cancer.** Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

Wegovy® pen is the **first and only FDA-approved** once-weekly GLP-1 RA medication to treat adults with MASH and liver scarring,† along with a reduced calorie diet and increased physical activity.

†Moderate to advanced liver scarring (fibrosis) without cirrhosis.

GLP-1 RA, glucagon-like peptide-1 receptor agonist.

Improved liver scarring and no worsening of MASH

In the study, significantly more adults taking Wegovy® achieved **an improvement in liver scarring and no worsening of MASH‡** compared with those taking placebo. This means that more patients taking Wegovy® achieved:

- A decrease in liver scarring by at least one stage in severity
- No worsening of MASH

IMPROVED **LIVER SCARRING**

37% of adults taking Wegovy® achieved improved liver scarring and no worsening of MASH

vs **22%** of adults taking placebo

‡Defined as at least one stage improvement in liver scarring and no worsening of steatohepatitis (defined as no increase from baseline in score for ballooning, lobular inflammation, or steatosis).

Important Safety Information

Do not use Wegovy® if:

- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy®. See "**What are the possible side effects of Wegovy®?**" for symptoms of a serious allergic reaction

Wegovy® FlexTouch®: Do not share your Wegovy® FlexTouch® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:

- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

Potential side effects

What is the most important information I should know about Wegovy®?

Wegovy® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.

Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The most common side effects of Wegovy® in adults may include:

- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach (abdomen) pain
- Changes in skin sensations
- Headache
- Tiredness (fatigue)
- Upset stomach
- Dizziness
- Feeling bloated
- Belching
- Low blood sugar in people with type 2 diabetes
- Gas
- Stomach flu
- Heartburn
- Hair loss

Important Safety Information

Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: (cont'd)

- are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. It is not known if Wegovy® when received through an injection passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

Discuss with your care team

Tell your health care professional (HCP) if you have any side effects. Pay attention to how you're feeling and talk about any side effect that does not go away or bothers you.

Take the time to learn about your medicine

You can learn more about Wegovy® in the Medication Guide and Instructions for Use at **www.novo-pi.com/wegovy.pdf#guide**.

Important Safety Information

What are the possible side effects of Wegovy®?

Wegovy® may cause serious side effects, including:

- **inflammation of your pancreas (pancreatitis).** Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back
- **gallbladder problems.** Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

A look at taking **Wegovy®** (semaglutide) injection 2.4 mg

Scan the QR code to learn about **dosing and administration**

Before using your Wegovy® pen for the first time, discuss how to inject Wegovy® with your health care professional.

Also, be sure to read the full step-by-step Instructions for Use to help guide you through the process.

Important Safety Information

What are the possible side effects of Wegovy®? (cont'd)

Wegovy® may cause serious side effects, including: (cont'd)

- **increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas.** This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

Important Safety Information

What are the possible side effects of Wegovy®? (cont'd)

Wegovy® may cause serious side effects, including: (cont'd)

- **dehydration leading to kidney problems.** Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

Ways to save on **Wegovy®** (semaglutide) injection 2.4 mg

Find out if you can save on a Wegovy® prescription

You can sign up for the savings offer by scanning the QR code below or by text. Text SAVE to 83757 to get started.*

With commercial insurance	Self pay
Pay as little as **$25** per month†	Starting at **$199** per month‡ Limited time intro offer, $199 per month for the first 2 months, 0.25 mg or 0.5 mg doses, then $349 per month.‡‡

Scan to request your **savings card**

*Text SAVE to 83757 to receive your Wegovy® digital savings offer and optional refill reminders. Message and data rates may apply. Message frequency varies. Text HELP for help. Text STOP to quit. See Terms and Conditions and privacy policy at WegovyText.com.

† A 28 day supply of the Wegovy® pen equals one month of treatment. Pay as little as $25 (maximum savings $100/month). For eligible patients only. Novo Nordisk® may modify or cancel this program at any time. See WegovyTerms.com for full terms.

‡ For eligible patients new to the Wegovy® Savings offer and fill through NovoCare® Pharmacy- Pay $199/month for 0.25 mg and 0.5 mg doses for up to two monthly fills through December 31, 2026. Thereafter price is $349 month. Full terms: NovoCarePharmacy.com and WegovyTerms.com.

Important Safety Information

What are the possible side effects of Wegovy®? (cont'd)

Wegovy® may cause serious side effects, including: (cont'd)

- **serious allergic reactions.** Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **change in vision in people with type 2 diabetes.** Tell your healthcare provider if you have changes in vision during treatment with Wegovy®
- **increased heart rate.** Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

Not sure about your **insurance coverage?**

We have some cost, coverage, and additional resources **that may help**. Learn more at **WegovyCoverageCheck.com**

Still have questions? **Help is a phone call away**

Call the Wegovy® Navigation Line at **1-833-4-WEGOVY**

Monday through Friday, 9:00 AM to 6:00 PM, ET.

Free Trial of Wegovy® for MASH with liver scarring

Patients diagnosed with MASH who are new to Wegovy® and have commercial or no insurance may be eligible to receive a free month's supply of the 0.25-mg dosage.§

§28-day supply equivalent to 1 month of treatment. Novo Nordisk® reserves the right to modify or cancel this program at any time. Government beneficiaries excluded. See Terms & Conditions for Free Trial Offer eligibility here: https://www.novocare.com/eligibility/mash-program-terms.html.

Important Safety Information

What are the possible side effects of Wegovy®? (cont'd)

Wegovy® may cause serious side effects, including: (cont'd)

- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

Wegovy® is an injectable prescription medicine to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, along with a reduced calorie diet and increased physical activity.

ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg

Find more support from Wegovy®

Scan to explore helpful resources to stay on track with your MASH treatment goals

Important Safety Information

What are the possible side effects of Wegovy®? (cont'd)

The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.

Wegovy® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch** or call **1-800-FDA-1088**.
FDA, US Food and Drug Administration.

Please see Important Safety Information throughout. Please click here for Prescribing Information, including Medication Guide.

Wegovy® and FlexTouch® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved.
Printed in the U.S.A. US26SN00213 August 2026

novo nordisk®